Transcatheter aortic valve implantation.
With the improvement in the overall life expectancy, the incidence of aortic stenosis has been increasing. Although aortic valve replacement is a standard therapy, many patients do not undergo surgery for various reasons, including advanced age or the presence of multiple comorbidities. Transcatheter aortic valve implantation (TAVI) has been proposed as a less invasive and equally effective treatment for inoperable or high-risk symptomatic aortic stenosis. Numerous rigorous global clinical trials, as well as a pivotal clinical trial in Japan, have been conducted. In this review, we provide data on the development of TAVI worldwide and discuss the prospects for TAVI in Japan.
Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, 2-2 Yamada-Oka, Suita, Osaka, 565-0871, Japan, sawa@surg1.med.osaka-u.ac.jp.
Yoshiki
Y
Sawa
D000368:Aged; D000369:Aged, 80 and over; D001024:Aortic Valve Stenosis / Q000601:surgery*; D000075202:Contraindications; D003362:Cost-Benefit Analysis; D004452:Echocardiography; D006801:Humans; D007431:Intraoperative Complications; D007564:Japan; D019060:Minimally Invasive Surgical Procedures / Q000379:methods*; D025321:Surgery, Computer-Assisted / Q000379:methods*; D065467:Transcatheter Aortic Valve Replacement / Q000191:economics / Q000379:methods*; D018084:Ultrasonography, Interventional